Oxurion NV announces full enrollment in its Phase 1 trial evaluating the safety of its plasma kallikrein inhibitor THR-149 fo...
24 Aprile 2019 - 7:30AM
Leuven, Belgium,
24 April 2019 - Oxurion NV (Euronext Brussels: OXUR), a
biopharmaceutical company developing innovative treatments to
preserve vision in patients with diabetic eye disease, announces
today that it has completed enrollment of its Phase 1 study of
THR-149, a novel plasma kallikrein (PKal) inhibitor for the
treatment of Diabetic Macular Edema (DME). A total of 15 patient
have been recruited. The study enrolled faster than anticipated and
initial data will be released by early Q3 2019.
The Phase 1 trial is designed to
evaluate the safety of a single intravitreal (IVT) injection of
THR-149 a novel PKal inhibitor, of 3 ascending dose levels in
subjects with visual impairment due to center-involved DME (CI-DME)
(NCT03511898).
Activation of the PKal enzyme has
been shown to induce retinal vascular permeability, microaneurysm
and inflammation. Based on literature data, patients with DME have
elevated levels of plasma kallikrein.
Encouraging preclinical studies
involving THR-149 were published in The Journal of Medicinal
Chemistry in March 2018. These data demonstrate the potency and
efficacy of bicyclic peptide inhibitors of PKal, such as THR-149,
via a VEGF-independent pathway.
Patrik De Haes,
M.D., CEO of Oxurion nv, commented: "We are
delighted to have completed patient recruitment in this important
clinical trial earlier than anticipated. This study has been
designed to assess THR-149's safety profile and to provide the
information needed to plan the future clinical development plan of
this novel plasma kallikrein inhibitor for the treatment of
DME."
END
For further
information please contact:
Oxurion
NV
Wouter Piepers,
Global Head of Investor Relations & Corporate
Communications
+32 16 75 13 10 / +32 478 33 56 32
wouter.piepers@oxurion.com
|
EU - Citigate Dewe Rogerson
David Dible/ Sylvie Berrebi
Tel: +44 20 7638 9571
oxurion@citigatedewerogerson.com |
US - LifeSci Public Relations
Alison Chen
+1 646-876-4932
achen@lifescipublicrelations.com |
About Oxurion
Oxurion (Euronext Brussels: OXUR)
is a biopharmaceutical company currently developing a competitive
pipeline of disease-modifying drug candidates for diabetic eye
disease, a leading cause of blindness in people of working age
worldwide.
Oxurion's most advanced drug
candidate is THR-317, a PlGF inhibitor for the treatment of
diabetic macular edema (DME), which is currently in a Phase 2 study
in combination with Lucentis®. THR-317 is
also being evaluated in a Phase 2 study for the treatment of
Idiopathic Macular Telangiectasia Type 1 (MacTel 1), a rare retinal
disease that affects the macula and can lead to vision loss.
Oxurion has two further pipeline
candidates, THR-149, a plasma kallikrein inhibitor being developed
for the treatment of DME; and THR-687, a pan-RGD integrin
antagonist in development for the treatment of diabetic retinopathy
and DME. Both THR-149 and THR-687 are in Phase 1 clinical
studies.
Oxurion is headquartered in
Leuven, Belgium, and is listed on the Euronext Brussels exchange
under the symbol OXUR.
More information is available at
www.oxurion.com.
Important information about forward-looking
statements
Certain
statements in this press release may be considered
"forward-looking". Such forward-looking statements are based on
current expectations, and, accordingly, entail and are influenced
by various risks and uncertainties. The Company therefore cannot
provide any assurance that such forward-looking statements will
materialize and does not assume an obligation to update or revise
any forward-looking statement, whether as a result of new
information, future events or any other reason. Additional
information concerning risks and uncertainties affecting the
business and other factors that could cause actual results to
differ materially from any forward-looking statement is contained
in the Company's Annual Report. This press
release does not constitute an offer or invitation for the sale or
purchase of securities or assets of Oxurion in any
jurisdiction. No securities of Oxurion may be offered or sold
within the United States without registration under the U.S.
Securities Act of 1933, as amended, or in compliance with an
exemption therefrom, and in accordance with any applicable U.S.
state securities laws.
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Oxurion NV via Globenewswire
Grafico Azioni Thermon (NYSE:THR)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Thermon (NYSE:THR)
Storico
Da Giu 2023 a Giu 2024